QQQ   353.12 (+2.32%)
AAPL   162.86 (+1.93%)
MSFT   302.79 (+4.96%)
FB   303.25 (+1.03%)
GOOGL   2,636.05 (+3.83%)
AMZN   2,846.72 (+1.68%)
TSLA   954.10 (+3.89%)
NVDA   235.12 (+5.32%)
BABA   116.30 (-2.38%)
NIO   23.77 (-0.08%)
AMD   114.24 (+2.80%)
CGC   7.61 (+3.40%)
MU   84.06 (+4.14%)
GE   90.97 (-0.15%)
T   25.18 (-4.91%)
F   20.32 (+1.70%)
DIS   137.48 (+0.71%)
AMC   17.55 (+9.55%)
PFE   53.02 (+0.91%)
ACB   4.25 (+0.95%)
BA   197.42 (-3.27%)
QQQ   353.12 (+2.32%)
AAPL   162.86 (+1.93%)
MSFT   302.79 (+4.96%)
FB   303.25 (+1.03%)
GOOGL   2,636.05 (+3.83%)
AMZN   2,846.72 (+1.68%)
TSLA   954.10 (+3.89%)
NVDA   235.12 (+5.32%)
BABA   116.30 (-2.38%)
NIO   23.77 (-0.08%)
AMD   114.24 (+2.80%)
CGC   7.61 (+3.40%)
MU   84.06 (+4.14%)
GE   90.97 (-0.15%)
T   25.18 (-4.91%)
F   20.32 (+1.70%)
DIS   137.48 (+0.71%)
AMC   17.55 (+9.55%)
PFE   53.02 (+0.91%)
ACB   4.25 (+0.95%)
BA   197.42 (-3.27%)
QQQ   353.12 (+2.32%)
AAPL   162.86 (+1.93%)
MSFT   302.79 (+4.96%)
FB   303.25 (+1.03%)
GOOGL   2,636.05 (+3.83%)
AMZN   2,846.72 (+1.68%)
TSLA   954.10 (+3.89%)
NVDA   235.12 (+5.32%)
BABA   116.30 (-2.38%)
NIO   23.77 (-0.08%)
AMD   114.24 (+2.80%)
CGC   7.61 (+3.40%)
MU   84.06 (+4.14%)
GE   90.97 (-0.15%)
T   25.18 (-4.91%)
F   20.32 (+1.70%)
DIS   137.48 (+0.71%)
AMC   17.55 (+9.55%)
PFE   53.02 (+0.91%)
ACB   4.25 (+0.95%)
BA   197.42 (-3.27%)
QQQ   353.12 (+2.32%)
AAPL   162.86 (+1.93%)
MSFT   302.79 (+4.96%)
FB   303.25 (+1.03%)
GOOGL   2,636.05 (+3.83%)
AMZN   2,846.72 (+1.68%)
TSLA   954.10 (+3.89%)
NVDA   235.12 (+5.32%)
BABA   116.30 (-2.38%)
NIO   23.77 (-0.08%)
AMD   114.24 (+2.80%)
CGC   7.61 (+3.40%)
MU   84.06 (+4.14%)
GE   90.97 (-0.15%)
T   25.18 (-4.91%)
F   20.32 (+1.70%)
DIS   137.48 (+0.71%)
AMC   17.55 (+9.55%)
PFE   53.02 (+0.91%)
ACB   4.25 (+0.95%)
BA   197.42 (-3.27%)

7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead - 1 of 7

 

#1 - Pfizer (NYSE:PFE)

Pfizer logo

We understand that starting with Pfizer (NYSE:PFE) may be off-putting to some investors. The company is polarizing, to say the least. However, as the omicron variant reminds us, the pandemic may be closer to an end than the beginning, but it still has some chapters to go. That means that Pfizer is likely to continue to generate strong revenue and earnings.

PFE stock is up 42% in 2021 easily outpacing the S&P 500 and to be fair the consensus price target of analysts tracked by MarketBeat shows the stock trading has peaked. However, the company released its last earnings report prior to the discovery of the omnicron variant. Since then, the stock has received several raised price targets from analysts.

And this bullish view is supported by Dan Ushman, CEO and Founder of the technical analysis software firm TrendSpider who believes PFE stock is displaying a strong technical outlook. In a research note, Ushman noted that PFE stock recently broke through a level of resistance and is now trading at an all-time high. Ushman believes that Pfizer may retest recent lows, but if it can stay above those levels it could break out to the upside. 

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.Read More 
Current Price
$53.15
Consensus Rating
Buy
Ratings Breakdown
11 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$57.42 (8.0% Upside)





Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.